AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 117 filers reported holding AUDENTES THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.70 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $44,609,000 | -31.2% | 1,588,069 | -7.3% | 0.85% | -15.7% |
| Q2 2019 | $64,857,000 | -8.4% | 1,713,069 | -5.6% | 1.00% | -8.4% |
| Q1 2019 | $70,821,000 | +75.4% | 1,815,000 | -4.1% | 1.10% | +46.9% |
| Q4 2018 | $40,369,000 | -53.2% | 1,893,500 | -13.1% | 0.75% | -28.3% |
| Q3 2018 | $86,306,000 | -13.6% | 2,180,000 | -16.6% | 1.04% | -12.8% |
| Q2 2018 | $99,919,000 | -5.6% | 2,615,000 | -25.8% | 1.19% | -9.1% |
| Q1 2018 | $105,839,000 | -18.0% | 3,522,100 | -14.7% | 1.31% | -19.6% |
| Q4 2017 | $129,051,000 | +11.6% | 4,129,638 | 0.0% | 1.63% | +47.7% |
| Q3 2017 | $115,671,000 | +25.9% | 4,129,638 | -14.0% | 1.10% | +14.7% |
| Q2 2017 | $91,855,000 | +12.3% | 4,801,638 | 0.0% | 0.96% | +3.9% |
| Q1 2017 | $81,820,000 | -6.7% | 4,801,638 | 0.0% | 0.93% | -17.1% |
| Q4 2016 | $87,726,000 | +2.6% | 4,801,638 | 0.0% | 1.12% | +14.8% |
| Q3 2016 | $85,517,000 | – | 4,801,638 | – | 0.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEXTHERA CAPITAL LP | 294,013 | $11,131,000 | 9.27% |
| GREAT POINT PARTNERS LLC | 1,922,937 | $72,802,000,000 | 8.08% |
| Versant Venture Management, LLC | 553,916 | $20,971,260,000 | 6.11% |
| Foresite Capital Management III, LLC | 315,331 | $11,938,000 | 3.92% |
| Casdin Capital, LLC | 965,000 | $36,534,900,000 | 3.42% |
| Sofinnova Investments, Inc. | 933,640 | $35,348,000 | 3.25% |
| Opaleye Management Inc. | 280,000 | $10,601,000 | 3.23% |
| Redmile Group, LLC | 2,972,167 | $112,526,000 | 3.18% |
| PFM Health Sciences, LP | 3,228,679 | $122,238,000 | 2.32% |
| Eversept Partners, LP | 159,526 | $6,039,654 | 1.69% |